| Trial ID: | L0151 |
| Source ID: | NCT01094158
|
| Associated Drug: |
Aramchol
|
| Title: |
Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis
|
| Acronym: |
Aramchol003
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-Alcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis|Metabolic Syndrome
|
| Interventions: |
Drug: Aramchol|Drug: Placebo
|
| Outcome Measures: |
The difference between initial and final liver triglyceride concentration (measured by NMRS) comparing the Aramchol and placebo treated patients.|Comparing secondary variables of liver, metabolic and endothelial functions between the Aramchol and the placebo arms.
|
| Sponsor/Collaborators: |
Galmed Medical Reserch|Tel-Aviv Sourasky Medical Center|Beilinson Hospital, Petach Tikva,Israel|Meir Medical Center|Kaplan Hospital ,Rehovot,Israel|Soroka Hospital,Beer Sheva,Israel|Hadassah Medical Organization|Hillel Yaffe Medical Center|Rambam Hospital
|
| Gender: |
All
|
| Age: |
18 Years to 75 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 2
|
| Enrollment: |
60
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
|
| Start Date: |
November 2010
|
| Completion Date: |
January 2012
|
| Results First Posted: |
--
|
| Last Update Posted: |
January 31, 2012
|
| Locations: |
Soroka Medical Center, Beer Sheva, Israel|Hillel Yaffe Medical Center, Hadera, Israel|Rambam, Haifa, Israel|The Lady Davis Carmel Medical Center, Haifa, Israel|Hadassah Ein Kerem M.C, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Holy Family HOSPITAL, Nazareth, Israel|Belinson,Rabin Medical Center, Petah Tikva, Israel|Kaplan M.C, Rehovot, Israel|Safed Ziv Hospital, Safed, Israel|The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
|
| URL: |
https://ClinicalTrials.gov/show/NCT01094158
|
